Literature DB >> 18922790

Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells.

Usha Gundimeda1, Jason Eric Schiffman, Divya Chhabra, Jourdan Wong, Adela Wu, Rayudu Gopalakrishna.   

Abstract

In this study, we show that methylselenol, a selenometabolite implicated in cancer prevention, did not directly inactivate protein kinase C (PKC). Nonetheless, its oxidation product, methylseleninic acid (MSA), inactivated PKC at low micromolar concentrations through a redox modification of vicinal cysteine sulfhydryls in the catalytic domain of PKC. This modification of PKC that occurred in both isolated form and in intact cells was reversed by a reductase system involving thioredoxin reductase, a selenoprotein. PKC isoenzymes exhibited variable sensitivity to MSA with Ca(2+)-dependent PKC isoenzymes (alpha, beta, and gamma) being the most susceptible, followed by isoenzymes delta and epsilon. Other enzymes tested were inactivated only with severalfold higher concentrations of MSA than those required for PKC inactivation. This specificity for PKC was further enhanced when MSA was generated within close proximity to PKC through a reaction of methylselenol with PKC-bound lipid peroxides in the membrane. The MSA-methylselenol redox cycle resulted in the catalytic oxidation of sulfhydryls even with nanomolar concentrations of selenium. MSA inhibited cell growth and induced apoptosis in DU145 prostate cancer cells at a concentration that was higher than that needed to inhibit purified PKC alpha but in a range comparable with that required for the inhibition of PKC epsilon. This MSA-induced growth inhibition and apoptosis decreased with a conditional overexpression of PKC epsilon and increased with its knock-out by small interfering RNA. Conceivably, when MSA is generated within the vicinity of PKC, it specifically inactivates PKC isoenzymes, particularly the promitogenic and prosurvival epsilon isoenzyme, and this inactivation causes growth inhibition and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922790      PMCID: PMC3259896          DOI: 10.1074/jbc.M807007200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

1.  Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice.

Authors:  N Fleshner; W R Fair; R Huryk; W D Heston
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

2.  Selenocompounds induce a redox modulation of protein kinase C in the cell, compartmentally independent from cytosolic glutathione: its role in inhibition of tumor promotion.

Authors:  R Gopalakrishna; Z H Chen; U Gundimeda
Journal:  Arch Biochem Biophys       Date:  1997-12-01       Impact factor: 4.013

3.  Cancer-preventive selenocompounds induce a specific redox modification of cysteine-rich regions in Ca(2+)-dependent isoenzymes of protein kinase C.

Authors:  R Gopalakrishna; U Gundimeda; Z H Chen
Journal:  Arch Biochem Biophys       Date:  1997-12-01       Impact factor: 4.013

Review 4.  Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.

Authors:  H E Ganther
Journal:  Carcinogenesis       Date:  1999-09       Impact factor: 4.944

5.  Induction of thioredoxin, thioredoxin reductase and glutaredoxin activity in mouse skin by TPA, a calcium ionophore and other tumor promoters.

Authors:  S Kumar; A Holmgren
Journal:  Carcinogenesis       Date:  1999-09       Impact factor: 4.944

6.  Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone.

Authors:  J A Watson; M G Rumsby; R G Wolowacz
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

7.  Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds.

Authors:  S Gromer; L D Arscott; C H Williams; R H Schirmer; K Becker
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

8.  Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial.

Authors:  I M Thompson; C A Coltman; J Crowley
Journal:  Prostate       Date:  1997-11-01       Impact factor: 4.104

Review 9.  Chemopreventive agents: selenium.

Authors:  G F Combs; W P Gray
Journal:  Pharmacol Ther       Date:  1998-09       Impact factor: 12.310

10.  Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C.

Authors:  S J Chen; E Klann; M C Gower; C M Powell; J S Sessoms; J D Sweatt
Journal:  Biochemistry       Date:  1993-02-02       Impact factor: 3.162

View more
  18 in total

1.  Imbalance in Protein Thiol Redox Regulation and Cancer-Preventive Efficacy of Selenium.

Authors:  Rayudu Gopalakrishna; Usha Gundimeda; Sarah Zhou; Kristen Zung; Kaitlyn Forell; Arne Holmgren
Journal:  React Oxyg Species (Apex)       Date:  2016-05-25

2.  The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.

Authors:  Michael Hagemann-Jensen; Franziska Uhlenbrock; Stephanie Kehlet; Lars Andresen; Charlotte Gabel-Jensen; Lars Ellgaard; Bente Gammelgaard; Søren Skov
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

Review 3.  [Prostate cancer prophylaxis by dietary supplements: more than just an illusion?].

Authors:  W Merkle
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

Review 4.  The A to Z of modulated cell patterning by mammalian thioredoxin reductases.

Authors:  Markus Dagnell; Edward E Schmidt; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2017-12-24       Impact factor: 7.376

5.  Missing Selectivity of Targeted 4β-Phorbol Prodrugs Expected to be Potential Chemotherapeutics.

Authors:  Ilari Tarvainen; Tomáš Zimmermann; Pia Heinonen; Maria Helena Jäntti; Jari Yli-Kauhaluoma; Virpi Talman; Henrik Franzyk; Raimo K Tuominen; Søren Brøgger Christensen
Journal:  ACS Med Chem Lett       Date:  2019-12-23       Impact factor: 4.345

Review 6.  Cysteine S-conjugate β-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents.

Authors:  Arthur J L Cooper; Boris F Krasnikov; Zoya V Niatsetskaya; John T Pinto; Patrick S Callery; Maria T Villar; Antonio Artigues; Sam A Bruschi
Journal:  Amino Acids       Date:  2010-03-22       Impact factor: 3.520

Review 7.  Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Authors:  Junxuan Lü; Jinhui Zhang; Cheng Jiang; Yibin Deng; Nur Özten; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2015-11-23       Impact factor: 2.900

Review 8.  Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.

Authors:  Dominika Radomska; Robert Czarnomysy; Dominik Radomski; Anna Bielawska; Krzysztof Bielawski
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

Review 9.  Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy.

Authors:  Carmen Sanmartín; Daniel Plano; Arun K Sharma; Juan Antonio Palop
Journal:  Int J Mol Sci       Date:  2012-08-02       Impact factor: 6.208

10.  Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells.

Authors:  Jie Liu; Jia Li; Jian-Fang Zhang; Xiao-Yan Xin
Journal:  Int J Mol Sci       Date:  2013-11-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.